Progenics Pharma (PGNX) Completes Enrollment of Phase 2/3 Clinical Trial of PSMA-Targeted PET/CT Imaging Agent PyL in Prostate Cancer

June 26, 2018 8:35 AM

Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX), an oncology company developing innovative medicines and imaging technology for targeting and treating cancer, today ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found